论文部分内容阅读
冠状动脉慢溢流(SCF)的现象是冠状动脉微血管紊乱,疾病的特点是对比度的延迟通道,不存在阻塞性心外膜冠状动脉的疾病。在经皮冠状动脉介入治疗(PCI)手术过程中发生慢溢流现象会导致严重的并发症。最近一些研究表明,对急性冠状动脉综合征患者给予静脉或冠脉内给药尼可地尔(KATP钾离子通道开放剂和硝酸盐的混合物)可以减少这种现象的发生率。然而,至于尼克地尔不仅会对急性冠脉综合征患者,而且对于非急性冠脉综合征患者均能阻止慢溢流现象的使用方法尚不清楚。因此,我们评估了静脉给予尼可地尔对有急性冠状动脉综合症且经历首选PCI手术的患者以及无急性冠状动脉综合症且经历后续PCI手术的患者发生慢溢流现象的效应。
Coronary slow flow (SCF) is a phenomenon characterized by coronary microvascular disturbances characterized by delayed contrast channels and absence of obstructive epicardial coronary arteries. Slow over-flow during percutaneous coronary intervention (PCI) can lead to serious complications. Recent studies have shown that intravenous or intracoronary administration of nicorandil (a mixture of KATP potassium channel openers and nitrates) to patients with acute coronary syndrome can reduce the incidence of this phenomenon. However, as for the use of nicadir not only in patients with acute coronary syndrome but also in patients with non-acute coronary syndromes, it is not clear how to prevent slow over-flow. Therefore, we evaluated the effect of intravenous nicorandil on patients with acute coronary syndrome who underwent the first PCI procedure, and patients who experienced no acute coronary syndrome and who underwent subsequent PCI.